2. Search Result
Search Result
Results for "

acly+inhibitor

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100396
    SQ22536
    35+ Cited Publications

    		 Adenylate Cyclase Metabolic Disease
    SQ22536 is an effective adenylate cyclase (AC) inhibitor.
    SQ22536
  • HY-127111
    NDI-091143
    2 Publications Verification

    		 ATP Citrate Lyase Cancer
    NDI-091143 is a potent and high-affinity human ATP-citrate lyase (ACLY) inhibitor with an IC50 of 2.1 nM (ADP-Glo assay), a Ki of 7.0 nM and a Kd of 2.2 nM. NDI-091143 inhibits ACLY catalysis allosterically, by stabilizing large conformational changes in the citrate domain that indirectly block the binding and recognition of citrate .
    NDI-091143
  • HY-175606
    EVT0185

    		ATP Citrate Lyase Cancer
    EVT0185 is an orally active ATP citrate lyase (ACLY) inhibitor. EVT0185 is converted to a CoA thioester in the liver by SLC27A2 and interacts with the CoA-binding site of ACLY. EVT0185-CoA inhibits ACLY activity with an IC50 of 2.5 μM. EVT0185 can phenocopy the immune and antitumour effects of genetic ACLY deletion. EVT0185 can increase tumour-infiltrating B cells and chemokine CXCL13 levels. EVT0185 can be used for the research of cancer, such as hepatocellular carcinoma (HCC) .
    EVT0185
  • HY-158783
    SACLAC

    		Ceramidase Bcl-2 Family LPL Receptor Apoptosis Neurological Disease
    SACLAC, a Ceramide analog, is a potent and covalent acid ceramidase (ASAH1; AC) inhibitor with a Ki of 97.1 nM. SACLAC effectively blocks AC activity and induces a decrease in sphingosine 1-phosphate (S1P) and total ceramide levels. SACLAC reduces the levels of splicing factor SF3B1 and alternative Mcl-1 mRNA splicing, increases pro-apoptotic Mcl-1S levels to induce apoptosis in acute myeloid leukemia (AML) cells. SACLAC reduces the leukemic burden in human AML xenograft mouse models .
    SACLAC
  • HY-172914
    ACLY-IN-1

    		ATP Citrate Lyase Cardiovascular Disease Metabolic Disease
    ACLY-IN-1 is an orally active ACLY inhibitor. ACLY-IN-1 exhibits potent ACLY inhibitory activity (IC50 = 8.3 nM) and high binding affinity (KD = 72.0 nM) to ACLY. ACLY-IN-1 demonstrates good pharmacokinetic profiles and a potent in vivo hypolipidemic effect .
    ACLY-IN-1
  • HY-P2939
    Chondroitinase AC

    		Apoptosis Biochemical Assay Reagents Cancer
    Chondroitinase AC is a hydrolytic enzyme. Chondroitinase AC degrades chondroitin sulfate A and chondroitin sulfate C. Chondroitinase AC inhibits the invasion and proliferation of melanoma cells and endothelial cells, and increases apoptosis. Chondroitinase AC can be used in research on melanoma and other cancers .
    Chondroitinase AC
  • HY-100396R
    SQ22536 (Standard)

    		Reference Standards Adenylate Cyclase Metabolic Disease
    SQ22536 (Standard) is the analytical standard of SQ22536. This product is intended for research and analytical applications. SQ22536 is an effective adenylate cyclase (AC) inhibitor.
    SQ22536 (Standard)
  • HY-115748A
    Mant-GTPγS triammonium

    		Adenylate Cyclase Cardiovascular Disease
    Mant-GTPγS triammonium, a GTP mimetic, is a potent competitive adenylyl cyclase (AC) inhibitor. Mant-GTPγS triammonium is a potent YdeH inhibitor .
    Mant-GTPγS triammonium
  • HY-RI01635
    hsa-miR-548ac inhibitor

    		MicroRNA Cancer
    hsa-miR-548ac inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    hsa-miR-548ac inhibitor
    hsa-miR-548ac inhibitor
  • HY-163106
    W000113414_I13

    		Ceramidase Cancer
    W000113414_I13 is an acid ceramidase (AC) inhibitor. W000113414_I13 exhibits dose-dependent inhibition of AC with an IC50 value of 6.6?μM. W000113414_I13 can be used for the research of cancer .
    W000113414_I13
  • HY-137750
    MANT-cGMP

    		Adenylate Cyclase Cardiovascular Disease Neurological Disease Cancer
    MANT-cGMP, a ribose-substituted nucleotide, is an adenylyl cyclase (AC) inhibitor with a Ki of 100 μM and a pKi of 4. MANT-cGMP can be used for the study of heart failure, cancer, and neurological disorders .
    MANT-cGMP
  • HY-179591
    BGT-002

    326E

    		 ATP Citrate Lyase PPAR Metabolic Disease
    BGT-002 (326E) is an orally active dual ACLY inhibitor and PPARα agonist. BGT-002 reduces lipogenesis by inhibiting synthesis and promoting efflux. BGT-002 demonstrates efficacy in ameliorating metabolic dysfunction-associated steatohepatitis (MASH) and improving hyperlipidemia in vivo. BGT-002 can be used for hypercholesterolemia and MASH research .
    BGT-002
  • HY-137744
    MANT-GppNHp

    		Adenylate Cyclase Nucleoside Antimetabolite/Analog Infection
    MANT-GppNHp is a competitive adenyl cyclase (AC) inhibitor. MANT-GppNHp is a fluorescently labeled GTP (HY-113225) analogue. MANT-GppNHp interacts with the hydrophobic pocket near the AC catalytic site through its MANT group, thereby directly blocking the binding of the substrate ATP. MANT-GppNHp can be used to study diseases related to the increased activity of AC (such as cholera) .
    MANT-GppNHp
  • HY-182750
    ACLY-IN-3

    		ATP Citrate Lyase Inflammation/Immunology
    ACLY-IN-3 is an ATP-citrate lyase (ACLY) inhibitor with an IC50 of 0.036 μM and a target Kd of 0.54 μM. ACLY-IN-3 interacts with the allosteric binding site of ACLY to inhibit its activity. ACLY-IN-3 exhibits excellent lipid-lowering effects and alleviates hepatic inflammation and liver fibrosis. ACLY-IN-3 can be used for the research of metabolic dysfunction-associated steatohepatitis .
    ACLY-IN-3
  • HY-182751
    ACLY-IN-4

    		ATP Citrate Lyase Inflammation/Immunology
    ACLY-IN-4 is an ATP-citrate lyase (ACLY) inhibitor with an IC50 of 0.022 μM and a Kd of 0.19 μM. ACLY-IN-4 binds to the allosteric binding site of ACLY. ACLY-IN-4 exhibits hypolipidemic, anti-steatotic, insulin sensitivity-improving, anti-oxidative stress, anti-inflammatory and anti-fibrotic activities. ACLY-IN-4 alleviates hepatic steatosis, systemic insulin resistance, oxidative stress, hepatic inflammation and fibrosis. ACLY-IN-4 can be used for the research of metabolic dysfunction-associated steatohepatitis .
    ACLY-IN-4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: